Sapience Therapeutics
Sapience Therapeutics is a clinical-stage biotechnology company developing peptide therapeutics that target hard-to-treat cancers.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Sapience Therapeutics is a clinical-stage biotechnology company focused on eliminating hard-to-treat cancers. It describes its SPEARs™ as acting inside cancer cells and its SPARCs™ as acting on the outside, and states that two SPEARs, lucicebtide (formerly ST101) and ST316, are in Phase 2 trials. The company also describes its ADAPT™ and PADS™ peptide discovery and development platforms. Barry Kappel is the founder, President, Chief Executive Officer and Director.
History
Sapience Therapeutics is a clinical-stage biotechnology company focused on eliminating hard-to-treat cancers. It states that it has advanced peptide therapeutics by bringing together experts across peptide chemistry, molecular biology, immunology and oncologic drug development. The company describes its SPEARs™ as acting inside cancer cells and its SPARCs™ as acting on the outside, and states that two SPEARs, lucicebtide (formerly known as ST101) and ST316, are in Phase 2 trials. It also describes its ADAPT™ and PADS™ platforms as purpose-built to maximize the translational potential of drug candidates. Barry Kappel is the founder, President, Chief Executive Officer and Director of Sapience Therapeutics.
Products and positioning
Clinical-stage biotechnology company bringing expertise and innovation to eliminating hard-to-treat cancers through peptide therapeutics.
Lucicebtide (ST101)
ST316
Recent events
Sapience Therapeutics appoints J. Andrew Sanford to its board[5]
Reported:
Sapience Therapeutics announced that it appointed J. Andrew Sanford to its board of directors.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sapience-therapeutics · Editorial policy · How profiles are compiled